-+ 0.00%
-+ 0.00%
-+ 0.00%

Initiator Pharma Q3 Net Loss Doubles to DKK 8.5 Million

PUBT·11/20/2026 07:34:05
Initiator Pharma Q3 Net Loss Doubles to DKK 8.5 Million
  • Initiator Pharma’s Q3 2026 net loss doubled year-over-year to DKK 8.5 million, with no revenue.
  • External R&D costs rose year-over-year to DKK 6.18 million, reflecting CRO and CMC costs for the vulvodynia Phase IIa study.
  • Quarter-end cash and cash equivalents fell 51% year-over-year to DKK 14.17 million.
  • A November directed share issue to Klockhuset Investment will raise approximately DKK 8.2 million before transaction costs.
  • Final patient dosing in the Phase IIa pudafensine study in women with vulvodynia was completed in October.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Initiator Pharma A/S published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.